Navigation Links
Optimizing cell therapy against tumors is a balancing ACT

Adoptive cell transfer (ACT) therapy is used to treat patients with metastatic solid tumors. ACT involves the removal of some of the patient's cancer cells, and some of their immune T cells. When the cells are mixed together, specific parts of the cancer cells that stimulate the T cells to cause an immune attack can be identified. The T cells get expanded and re-infused into the patient to mount an immunological, anti-cancer response against the tumors. One of the challenges faced is selecting the appropriate T cells with proper antigen specificity.

In a new study appearing in the June 1 print issue of The Journal of Clinical Investigation, Nicholas Restifo and colleagues identified which cells are optimal for treating large, vascularized, established tumors. The authors use a mouse model that mimics the human clinical situation. They find that phenotypic and functional qualities of T cells are associated with the ability of ACT to cause regression of large, established melanomas. Seemingly paradoxical, naïve and early effector T cells are more effective for tumor treatment than more differentiated T cells.

In an accompanying commentary, Daniel Speiser and Pedro Romero write, "optimal therapeutic efficacy may depend on different T cell selection and preparation strategies" and these findings indicate that a pragmatic strategy for ACT is to keep the in vitro T cell expansion phase as short as possible to keep them naïve. These findings are important for development of improved adoptive immunotherapy approaches for treating tumors and established infectious diseases.

TITLE: Acquisition of full effector function in vitro paradoxically impairs the in vivo anti-tumor efficacy of adoptively transferred CD8+ T cells

TITLE: Towards improved immunocompetence of adoptively transferred CD8+ T cells


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2016)... 11, 2016  higi, the leading retail and ... locations, web and mobile, today announced it has ... existing investors. --> ... further innovate higi,s health platform – its network ... – including expanding services and programs to retail ...
(Date:1/7/2016)... 7, 2016 This BCC Research report studies ... technologies and devices, identifying newer markets and exploring the ... of biometric devices. Includes forecast from 2015 to 2020. ... markets and explore the expansion of the present application ... type of biometric technology, determine its current market size, ...
(Date:1/6/2016)... PLEASANTON, Calif. , Jan. 6, 2016  Varam ... SayPay as their trusted partner to deliver advanced authentication ... other financial services to the poor. A loan of ... in their lives, giving them the ability to purchase ... machine to make clothing, or stock for a local ...
Breaking Biology News(10 mins):
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/5/2016)... , February 5, 2016 ... a biotechnology company focused on developing products for Regenerative ... requested Rare Pediatric Disease Designation (RPDD) from the US ... (RP) with MANF. MANF was previously granted orphan drug ... --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... talent development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Sangamo BioSciences, ... genome editing, announced today that Edward Lanphier , ... update on the progress of Sangamo,s ZFP Therapeutic ® ... business strategy at 2:40 pm ET on Thursday, February ... Annual Global Healthcare Conference. The conference is being held ...
Breaking Biology Technology: